E-Scape Bio is a preclinical stage biopharmaceutical company focused on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases.
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia`s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners` development unit, Validae Health.
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.
We are a San Francisco Bay Area-based research stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases. We are developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress.
Arizona Benefit Plans is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.